Condition

Non-Small Cell Lung Carcinoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 38 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials38

Recruiting4

Common interventions25

Lead sponsors shown15

Clinical trials

38 shown

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid TumorsNCT07284186 · 2025-12-01

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CTNCT06222489 · 2025-03-03

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750 · 2020-10-29

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerNCT05642195 · 2026-10-12

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)NCT06694454 · 2026-10-12

Study of IK-595 in RAS- or RAF-altered Advanced TumorsNCT06270082 · 2023-12-18

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNCT05358249 · 2022-10-24

ACTIVE_NOT_RECRUITING

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.NCT05110196 · 2022-09-03

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLCNCT04984811 · 2021-11-15

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing SurgeryNCT03678350 · 2021-09-17

NEUWAVE Flexible Probe Study #2NCT03713099 · 2020-07-31

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be ControlledNCT06282991 · 2020-07-22

Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung CancerNCT03735095 · 2020-02-12

Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing TreatmentNCT03731585 · 2018-11-15

ACTIVE_NOT_RECRUITING

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesNCT03590054 · 2018-08-20

Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung CancerNCT02937402 · 2018-04-05

Social Media Listening in Improving Clinical Trial Recruitment in Patients With CancerNCT03408561 · 2017-11-08

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung CancerNCT03054038 · 2017-07-20

Patient Navigation for Lung Cancer Screening in an Urban Safety-Net SystemNCT02758054 · 2017-06-16

Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLCNCT02879097 · 2016-12-01

Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.NCT02922777 · 2016-11-01

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyNCT02432963 · 2016-06-14

ACTIVE_NOT_RECRUITING

CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation TherapyNCT02693080 · 2016-01-19

IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain MetastasesNCT02556593 · 2015-09-01

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)NCT02142738 · 2014-08-25

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung CancerNCT02186847 · 2014-08-01

Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without ChemotherapyNCT02062632 · 2014-04-14

Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)NCT01915524 · 2013-04-01

Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic Body Radio Therapy SystemNCT02224547 · 2013-01-01

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)NCT00753415 · 2008-08-01

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung CancerNCT00540514 · 2007-11-01

LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With ChemotherapyNCT00328588 · 2006-12-01

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung CancerNCT00365183 · 2006-06-01

Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung CarcinomaNCT00192829 · 2005-06-01

FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung CarcinomaNCT00086333 · 2004-07-01

Detection of Plasma DNA in Non Small Cell and Small Cell Lung Cancer PatientsNCT00213798 · 2003-12-01

Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung CancerNCT00081315 · 2003-11-01

Common interventions

Leading sponsors

Merck Sharp & Dohme LLC 2 National Cancer Institute (NCI) 2 Novartis Pharmaceuticals 2 Pfizer 2 Roswell Park Cancer Institute 2 University of Texas Southwestern Medical Center 2 Vanderbilt-Ingram Cancer Center 2 Astellas Pharma Inc 1 Celgene 1 Cipla BioTec Pvt. Ltd. 1 City of Hope Medical Center 1 CureVac 1 Ethicon, Inc. 1 Ikena Oncology 1 M.D. Anderson Cancer Center 1

Trial status mix

COMPLETED16

TERMINATED8

RECRUITING4

ACTIVE_NOT_RECRUITING3

UNKNOWN3

SUSPENDED2

WITHDRAWN2

Phase mix

PHASE115

PHASE215

NA6

PHASE34

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.